Faron Pharmaceuticals Limited (AIM:FARN) was one of the week’s significant gainers, with its stock rising by 35%.
This surge was driven by positive news from an unexpected source—the US Food & Drug Administration (FDA).
The FDA has effectively simplified and potentially fast-tracked a phase III clinical trial of Faron’s lead drug, Bexmarilimab, which is designed to treat myelodysplastic syndrome, a type of cancer affecting bone marrow.
The FDA acknowledged the challenges of running a comparative trial in patients whose disease has returned or is resistant to treatment.
Frontrunner
Instead, it proposed a phase III evaluation for newly diagnosed high-risk patients, eliminating the need for a separate study for patients with relapsed or refractory disease.
This guidance is part of the FDA's Project Frontrunner, an initiative aimed at accelerating the delivery of promising cancer treatments to patients.
For Faron, this means the proposed study could target a larger patient group, reduce development costs, and ultimately increase sales.
This development is likely to attract interest from major pharmaceutical companies, which often partner with and finance smaller companies like Faron to develop promising late-stage drugs.
AIM beats the Footsie
In the broader market, the week was relatively positive, with a 1.7% rise to 781.53, outperforming the FTSE 100, which remained flat during a slow week characterised by low trading volumes.
Mindflair was the week's biggest mover, with its stock soaring 94% after benefiting from a $450 million takeover in the virtual reality space, thanks to its investment in the Sure Valley Ventures Fund.
The deal is expected to generate around £4.65 million ($6 million) for Mindflair.
To put this into perspective, Mindflair’s current market capitalisation, even after this impressive run, is only £2.73 million.
Oil in a good cause
Among the top gainers, Mosman Oil and Gas Ltd (AIM:MSMN) saw a 53% increase in its share price following its announcement of a pivot into helium.
Similarly, Union Union Jack Oil PLC's (AIM:UJO, OTCQB:UJOGF) stock climbed 19% after announcing the commencement of drilling its second well in its American venture.
Broker Shore Capital suggested that Union Jack could see results from the initial well within a week, potentially leading to production within weeks and recouping drilling costs within months.
This project is considered low-risk and low-cost compared to UK-based projects.
UKOG on a downer after hydrogen lift
Sticking with the sector, UK Oil & Gas PLC (AIM:UKOG) experienced a 35% decline, erasing the previous week's gains following interest in hydrogen storage.
The wider junior oil and gas sector faced challenges, primarily due to the new Labour administration's unfavourable stance on new UK oil and gas exploration.
Deltic Energy PLC (AIM:DELT) bucked the trend with its shares rising 30% after it landed a licence in the last round under the Tory government – though these were only confirmed earlier this week.
The licence includes the Pharos and Teviot discoveries with the newly added area is seen as an extension of an existing Deltic exploration project.
Biome stumbles
On the downside, Biome Technologies PLC (AIM:BIOM) saw its value plummet by 48% after issuing a warning due to order delays in its bioplastics business.
Software groupCrimson Tide (AIM:TIDE) saw its stock tumble by 33% after potential bidder Ideagen PLC (AIM:IDEA) walked away from a deal.
Recruiter Norman Broadbent PLC (AIM:NBB) announced plans to take advantage of challenging sector conditions to make acquisitions.
However, the market responded to this announcement and a sharp drop in fee income last year by marking down the shares by 21%.
Finally, we turn to the Aquis Exchange for one of the year’s success stories. Incanthera PLC (AQSE:INC) inked another significant commercial deal for its skincare products.
Luxury cosmetics
Luxury cosmetics chain Marionnaud, part of the Watson Group retail conglomerate, is purchasing an additional 250,000 units, adding to a previous order of 100,000 units.
This deal brings Incanthera’s pipeline projects to around £10 million.
Despite the share price remaining largely rangebound this week, it has advanced from 6.5p to 28p over the past year, highlighting the success under CEO Tim McCarthy’s leadership.